# A Study to Evaluate Effects of KN056 in Healthy Participants

> **NCT05385575** · PHASE1 · COMPLETED · sponsor: **Suzhou Alphamab Co., Ltd.** · enrollment: 46 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** KN056 (0.1mg)
- **DRUG:** KN056 (0.3mg)
- **DRUG:** KN056 (1.0mg)
- **DRUG:** KN056 (3.0mg)
- **DRUG:** KN056 (6.0mg)
- **DRUG:** KN056 (12.0mg)
- **DRUG:** KN056 (18.0mg)

## Key facts

- **NCT ID:** NCT05385575
- **Lead sponsor:** Suzhou Alphamab Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-09
- **Primary completion:** 2023-12-22
- **Final completion:** 2024-02-29
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05385575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05385575, "A Study to Evaluate Effects of KN056 in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05385575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*